Clinical trials: fludarabine phosphate, open to volunteers
Acute Lymphocytic Leukemia
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
In this single-center, single-arm, prospective, Phase 1/2 study, the safety and efficacy of autologous BCOR and ZC3H12 genes knock-out CD19-targeting chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients…
- Trial name
- NCT07008885
- Testing
- CAR19TIF cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
B Cell Lymphoma
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
In this single-center, single-arm, prospective, Phase 1/2 study, the safety and efficacy of autologous BCOR and ZC3H12 genes knock-out CD19-targeting chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients…
- Trial name
- NCT07009002
- Testing
- CAR19TIF cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Non Hodgkin's Lymphoma
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
ATHENA chimeric antigen receptor (CAR)-T, a CD19-directed CAR-T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT06014073
- Testing
- TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T), Fludarabine, Cyclophosphamide
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Non-hodgkin Lymphoma
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double genes deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL)…
- Trial name
- NCT06323525
- Testing
- TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T), Fludarabine, Cyclophosphamide
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Acute Lymphoblastic Leukemia, Pediatric
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group.
- Trial name
- NCT03643276
- Testing
- Blinatumomab, Bortezomib, Cyclophosphamide
- Where
- 115 sites in Australia, Austria and 6 more
- Volunteers
- 5,000 people
- Sponsor
- Martin Schrappe
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS)
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
The goal of this clinical trial is to compare outcomes of two reduced intensity conditioning (RIC) regimens (fludarabine plus busulfan and fludarabine plus melphalan) in allogeneic hematopoietic stem cell transplantation (HSCT)…
- Conditions
- Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS), Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT05674539
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hematologic Diseases
Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation
This study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but…
- Trial name
- HIGHT (NCT06809699)
- Testing
- Busulfan (Busulfex), Cyclophosphamide (CTX), Fludarabine (Fludara)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- He Huang
Hepatocellular Carcinoma (HCC)
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
In this single-center, single-arm, prospective, open-label Phase 1/2 study, the safety and efficacy of autologous GPC3-targeted chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients with GPC3-positive…
- Trial name
- NCT06641453
- Testing
- GPC3-CART cells, Fludarabine Phosphate for Injection, Cyclophosphamide for Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus
The goal of this clinical trial is to test ATHENA CAR-T injection in adults with moderate to severe Systemic Lupus Erythematosus. The main question it aims to answer is: To evaluate the safety and tolerability of ATHENA CAR-T.
- Trial name
- NCT06373991
- Testing
- ATHENA CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 12 people
- Sponsor
- EdiGene Inc.
Multiple Sclerosis
AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis
One of the possible options for the treatment of MS at present is a high-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HIST-AHSCT), which is a highly effective treatment for…
- Trial name
- NCT05832515
- Testing
- Fludarabine Phosphate for Injection
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Non-hodgkin Lymphoma,B Cell
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
The team has developed the synthetic T cell receptor (TCR) and antigen receptor (STAR) T cells which were demonstrated safety in relapsed or refractory (r/r) B-cell non-Hodgkin' s lymphoma (B-NHL) (NCT05631912).
- Trial name
- NCT06321289
- Testing
- Allogeneic CD19-STAR T cell, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Oropharyngeal Cancer, Human Papilloma Virus
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic…
- Conditions
- Oropharyngeal Cancer, Human Papilloma Virus, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05582590
- Testing
- Fludarabine, Cyclophosphamide, NEXI-003 T cells
- Volunteers
- 36 people
- Sponsor
- NexImmune Inc.
Neuroblastoma
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor of embryonal origin in children. According to the International Neuroblastoma Risk Group (INRG) staging criteria and the International Neuroblastoma Staging System…
- Trial name
- NCT05303727
- Testing
- Anti Thymocyte Globulin, Fludarabine, Cyclophosphamide injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in…
- Trial name
- NCT05323201
- Testing
- fhB7H3.CAR-Ts, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative…
- Trial name
- CYCLE-1 (NCT04167696)
- Testing
- CYAD-02, ENDOXAN, Fludara
- Where
- 5 sites in United States, Belgium
- Volunteers
- 27 people
- Sponsor
- Celyad Oncology SA